Macrophage migration inhibitory factor: a potential biomarker for cardiovascular disease in persons with HIV?

Research output: Contribution to journalLetterResearchpeer-review

Abstract

In order to explore the utility of MIF as a biomarker in the setting of HIV infection, we examined the levels of MIF in HIV-infected individuals before and after commencing combination antiretroviral therapy (cART).
Original languageEnglish
Pages (from-to)1693 - 1694
Number of pages2
JournalAIDS
Volume28
Issue number11
DOIs
Publication statusPublished - 2014

Cite this

@article{29105b11817145a4906fd398f6e89d46,
title = "Macrophage migration inhibitory factor: a potential biomarker for cardiovascular disease in persons with HIV?",
abstract = "In order to explore the utility of MIF as a biomarker in the setting of HIV infection, we examined the levels of MIF in HIV-infected individuals before and after commencing combination antiretroviral therapy (cART).",
author = "Woolley, {Ian John} and Sally Ayoub and Crowe, {Suzanne Mary} and Westhorpe, {Clare Louise} and Catherine Cherry and Kumar Visvanathan and Morand, {Eric Francis}",
year = "2014",
doi = "10.1097/QAD.0000000000000276",
language = "English",
volume = "28",
pages = "1693 -- 1694",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams & Wilkins",
number = "11",

}

Macrophage migration inhibitory factor: a potential biomarker for cardiovascular disease in persons with HIV? / Woolley, Ian John; Ayoub, Sally; Crowe, Suzanne Mary; Westhorpe, Clare Louise; Cherry, Catherine; Visvanathan, Kumar; Morand, Eric Francis.

In: AIDS, Vol. 28, No. 11, 2014, p. 1693 - 1694.

Research output: Contribution to journalLetterResearchpeer-review

TY - JOUR

T1 - Macrophage migration inhibitory factor: a potential biomarker for cardiovascular disease in persons with HIV?

AU - Woolley, Ian John

AU - Ayoub, Sally

AU - Crowe, Suzanne Mary

AU - Westhorpe, Clare Louise

AU - Cherry, Catherine

AU - Visvanathan, Kumar

AU - Morand, Eric Francis

PY - 2014

Y1 - 2014

N2 - In order to explore the utility of MIF as a biomarker in the setting of HIV infection, we examined the levels of MIF in HIV-infected individuals before and after commencing combination antiretroviral therapy (cART).

AB - In order to explore the utility of MIF as a biomarker in the setting of HIV infection, we examined the levels of MIF in HIV-infected individuals before and after commencing combination antiretroviral therapy (cART).

UR - http://www.ncbi.nlm.nih.gov/pubmed/25232902

U2 - 10.1097/QAD.0000000000000276

DO - 10.1097/QAD.0000000000000276

M3 - Letter

VL - 28

SP - 1693

EP - 1694

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 11

ER -